Bexicaserin is under clinical development by Longboard Pharmaceuticals and currently in Phase II for Tuberous Sclerosis. According to GlobalData, Phase II drugs for Tuberous Sclerosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Bexicaserin LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bexicaserin overview

LP-352 (AN-352) is under development for the treatment of developmental and epileptic encephalopathies (DEEs) refractory focal epilepsies, Lennox-Gastaut Syndrome, dravet syndrome, tuberous sclerosis complex and CDKL5 deficiency disorder. It is administered by oral route. The drug candidate is developed based on arena neuroscience platform. It acts by targeting 5-Hydroxytryptamine Receptor 2C.

Longboard Pharmaceuticals overview

Longboard Pharmaceuticals (Longboard) is a clinical-stage biopharmaceutical company that discover and develops novel, transformative medicines for neurological diseases. The company’s pipeline program includes LP352, an oral 5-HT2c super agonist targeting dravet syndrome, lennox-gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder, and other epileptic disorders; LP143, a CB2 agonist against amyotrophic lateral sclerosis (ALS) and neuroinflammatory disorders; and LP659, S1P receptor modulator targeting multiple neuroinflammatory disorders. It is also developing medicines for the treatment of central nervous system neuroinflammatory diseases and epileptic encephalopathies. Longboard is headquartered in La Jolla, California, the US

For a complete picture of Bexicaserin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.